Track record · closed signal

Thermo Fisher Scientific Inc. (TMO) — closed signal from January 14, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 14, 2026 — -16.6% at the close.

Predicted vs. what happened

TMO price · publication thesis → realized outcomesplit-adjusted

$600.00 – $622.00Entry zone — fair-value band

$616.89Published — price the day we called it

$703.25Target — the price the thesis aimed for

$643.99Peak — highest point inside the window, not a realized return

$514.23Window close — end-of-window price, context only

What happened

Partial

Reached 31% of the predicted growth at its peak, without hitting the target.

At window close

-16.6%

realized, from the publication price to the last close inside the window

Peak gain

+4.4%

peak, from the publication price — not a realized return

S&P 500, same window

+0.9%

SPY over the identical days, dividend-adjusted

Window close

$514.23

last close inside the window, ended April 14, 2026

Peak price

$643.99

peak on January 22, 2026 — not a realized return

Days to target

—

The thesis — published January 14, 2026

Predicted growth

+14%

over the measurement window

Target price

$703.25

the price the thesis aimed for

Entry zone

$600.00 – $622.00

the fair-value band we waited for

Price at publication

$616.89

published January 14, 2026

Confidence

73%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Thermo Fisher should get more positive attention soon because it announced a partnership with NVIDIA to add AI to lab work and said reshoring is bringing new contracts. That makes the stock worth buying on a small pullback in the next 0-3 months. Big defensive stocks can underperform if riskier stocks rally, so be realistic.

Primary drivers

NVIDIA deal helps add AI to lab processes
Reshoring is creating new contract opportunities
Strong healthcare tools business draws conservative buyers
Pullback entry gives a clear, limited downside

How it played out

TMO: target was not reached

Lyra published TMO at $616.89 on January 14, 2026, with a short-term window through April 14, 2026. The thesis expected 14% growth toward $703.25. It pointed to the NVIDIA partnership adding artificial intelligence to lab work, reshoring contract opportunities, a defensive healthcare tools business, and a pullback entry with limited downside.

Inside the window, TMO peaked at $643.99 on January 22, 2026, with a 4.4% gain. That stayed below the target. It never got there. By April 14, 2026, the stock ended at $514.23. The thesis partially played out early, but it missed the target and finished below the publication price.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All TMO signals